Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
 1 a 20 de 630 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Sharrets J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer risk associated with lorcaserin — The FDA’s review of the CAMELLIA-TIMI 61 trial. N Engl J Med 2020;383:10 de septiembe. [Ref.ID 103713]
2.Tiene citas relacionadas Cita con resumen
Anónimo. Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA eequests withdrawal of weight-loss drug. U.S. Food and Drug Administration 2020:13 de febrero. [Ref.ID 103523]
3.Enlace a cita original Cita con resumen
Imperiale TF, Gruber RN, Stump TE, Emmett TW, Monahan PO. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: a systematic review and meta-analysis. Ann Intern Med 2019:26 de febrero. [Ref.ID 103034]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102844]
5. Cita con resumen
Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 2017;83:653-63. [Ref.ID 101935]
6. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
7.Enlace a cita original Cita con resumen
DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ 2017;357:j1455. [Ref.ID 101540]
9.Enlace a cita original Cita con resumen
Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJL, Forouzanfar MH. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ 2016;354:i3857. [Ref.ID 100708]
10.Enlace a cita originalTiene citas relacionadas
Baigent C. Aspirin for disease prevention: public policy or personal choice?. Ann Intern Med 2016;164:846-7. [Ref.ID 100467]
11.Enlace a cita originalTiene citas relacionadas
Bibbins-Domingo K, on behalf of the U.S. Preventive Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:836-45. [Ref.ID 100466]
12.Enlace a cita originalTiene citas relacionadas
Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:826-35. [Ref.ID 100465]
13.Enlace a cita originalTiene citas relacionadas
Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DSM, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:814-25. [Ref.ID 100464]
14.Enlace a cita originalTiene citas relacionadas
Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:804-13. [Ref.ID 100463]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP. Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:777-86. [Ref.ID 100462]
16. Cita con resumen
Redberg RF. Fecal blood testing or colonoscopy. What is the best method for colorectal cancer screening?. JAMA Intern Med 2016;176:1071-3. [Ref.ID 100420]
17. Cita con resumen
Anónimo. Riesgo de osteonecrosis mandibular asociado a la administración de aflibercept (Zaltrap) . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:16 de marzo. [Ref.ID 100031]
18.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cummings SR, Kiel DP, Black DM. Vitamin D supplementation and increased risk of falling. A cautionary tale of vitamin supplements retold. JAMA Intern Med 2016;176:febrero. [Ref.ID 100024]
20. Cita con resumen
Friis S, Riis AH, Erichsen R, Baron JA, Sorensen HT. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann Intern Med 2015;163:347-55. [Ref.ID 99513]
Seleccionar todas
 
 1 a 20 de 630 siguiente >>